Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include ROLONTIS, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Henderson, Nevada.
IPO Year:
Exchange: NASDAQ
Website: sppirx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/26/2023 | Mkt Outperform → Mkt Perform | JMP Securities |
Combination of Assertio's Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and Growth Across All Products Transaction Expected to be Significantly Accretive to Assertio in 2024 LAKE FOREST, Ill., July 31, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it has closed the proposed acquisition of Spectrum Pharmaceuticals, Inc. ("Spectrum") (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology. Assertio intends to provide updated guidance for the combined business
Stockholders From Both Assertio and Spectrum Have Overwhelmingly Voted in Support of the Transaction Transaction Expected to be Significantly Accretive to Assertio in 2024 LAKE FOREST, Ill. and BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that its stockholders and the stockholders of Spectrum Pharmaceuticals, Inc. ("Spectrum") (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology, have each approved the proposed definitive agreement pursuant to which Assertio will acquire Spectrum in an all-stock and
Recommendations from the Nation's Leading Independent Proxy Advisory Firms Recognize Value Creation Opportunity for Spectrum Stockholders and Strength of the Combined Company Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) ("Spectrum" or the "Company") announced today that the leading independent proxy advisory firms, Institutional Shareholder Services, Inc. ("ISS") and Glass Lewis & Co. ("Glass Lewis"), have each recommended that Spectrum stockholders vote "FOR" the proposal to adopt the Agreement and Plan of Merger ("Merger Agreement", and such proposal, the "Merger Proposal") at the upcoming special meeting of stockholders (the "Special Meeting") on July 27, 2023. Under the terms of the M
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) ("Spectrum" or the "Company"), a biopharmaceutical Company focused on novel and targeted oncology announced today that on May 16, 2023, the Company received a written notification from the Listing Qualifications Staff (the "Staff") of the Nasdaq Stock Market LLC (Nasdaq) that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Company previously received notification from the Staff on November 1, 2022, that its common stock failed to maintain a minimum bid price of $1.00 or more over the previous 30 consecutive business days, as required by the Nasdaq Listing Rules. Since t
-- Q1 2023 net sales of $15.6 million, an increase of 54% compared to Q4 2022 -- -- Company to be acquired by Assertio Holdings, Inc., delivering value to stakeholders in an all stock and contingent value rights (CVR) transaction -- -- Transaction expected to close in Q3 2023 -- Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a commercial stage biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended March 31, 2023, and provided a corporate update. First Quarter 2023 and Recent Business Update Net sales for Q1 2023 totaled $15.6 million, an increase of 54% compared to Q4 2022. 172 targeted acco
Complementary Commercial Growth Platforms Anticipated to Accelerate ROLVEDON™ (eflapegrastim-xnst) Injection Profitability and Diversify Revenue Streams Combination of Assertio's Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and Growth across All Products Transaction Expected to Be Accretive to Assertio's Adjusted EPS and Operating Cash Flow in 2024 Spectrum Stockholders Will Receive Upfront Consideration of 0.1783 ASRT shares per SPPI Share ($1.14 per share) Plus One CVR for Total Potential Consideration of up to $1.34 per Share Upfront Consideration Represents a Premium of 65% and the Total Potential Consideration Repres
-- First launch quarter for ROLVEDON™ (eflapegrastim-xnst) injection -- -- Q4 and full year net sales of $10.1 million -- -- Management to host webcast and conference call today at 8:30 a.m. ET / 5:30 a.m. PT -- Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period and full year ended December 31, 2022. Fourth Quarter 2022 and Recent Business Update First launch quarter for ROLVEDON, with net sales for the quarter and year ended December 31, 2022, totaling $10.1 million. Operating expenses decreased 45% year-over-year as the Company streamlined operation
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the fourth quarter and full year 2022 financial results and provide a corporate update on Wednesday, March 22, 2023, at 8:30 a.m. Eastern/5:30 a.m. Pacific. Conference Call and Webcast: Wednesday, March 22, 2023 @ 8:30 a.m. Eastern/5:30 a.m. Pacific To access the live call by phone, please go to this link (registration link) , and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. A live web
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that a permanent J-code, J1449, has been issued for ROLVEDON (eflapegrastim-xnst) Injection by the U.S. Centers for Medicare & Medicaid Services (CMS) effective as of April 1, 2023. "This is an important milestone in the ROLVEDON launch. A permanent J-code will enable a more efficient and predictable reimbursement in the outpatient setting. The combination of a permanent J-code on April 1, 2023 and ROLVEDON'S inclusion in the National Comprehensive Cancer Network® Supportive Care Guidelines (NCCN Guidelines) announced on December 6, 2022 are key elements in estab
-- Preliminary unaudited Q4 2022 net sales expected to be approximately $10 million -- -- Cash, cash equivalents and marketable securities of $75 million at 12/31/2022, which is expected to extend cash runway through 2024 -- Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology, today announced business highlights and preliminary ROLVEDON net sales for the quarter and year ended December 31, 2022. Business Highlights and Preliminary, Unaudited Financial Results Preliminary unaudited net sales for the quarter ending December 31, 2022 are expected to be approximately $10 million ROLVEDON was launched in the U.S. on October 18,